Bispecific Antibody-Drug Conjugates (BsADCs): An Emerging, Promising Anti-Cancer Therapeutic Modality With Improved Efficacy And Safety_Biocytogen Pharmaceuticals (Beijing) Co., Ltd._Bispecific,Antibody-Drug,Conjugates,BsADCs,An,Emerging,Promising,Anti-Cancer,Therapeutic,Modality,With,Improved,Efficacy,And,Safety

top

Please input keywords

ニュース&PR

お問い合わせ

JP

私たちの歩み

管理スタッフ

社会的責任

Antibody Assets

Project Integrum

Antibody discovery platforms

Clinical pipeline

Preclinical pipeline

動物・細胞モデル

Humanized animal models

KO mouse models

Immunodeficient mice/rats

Disease mouse models

Pharmacology service

Therapeutic area

Types of services

ゲノム編集

By technologies

Animal Breeding

Animal Cryopreservation

Animal Rederivation

Stock Information

Financial Reports

Listing Documents

Announcements & Notices

Corporate Governance

Investor Calendar

ウェビナー

Bispecific Antibody-Drug Conjugates (BsADCs): An Emerging, Promising Anti-Cancer Therapeutic Modality With Improved Efficacy And Safety

2023.07.19

Prev:Design and Screening of Bispec...

Next:Overcoming Difficulties in GPC...